Trial Profile
A Randomized Double-blind Crossover Study to Assess the Safety and Pharmacokinetics of Two Different Doses of Weekly Intravenous Administration of Alpha1-Proteinase Inhibitor (Human) Prolastin-C in Subjects With Alpha1-Antitrypsin Deficiency
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2018
Price :
$35
*
At a glance
- Drugs Alpha 1-antitrypsin (Primary)
- Indications Alpha 1-antitrypsin deficiency
- Focus Adverse reactions
- Acronyms SPARK
- Sponsors Grifols
- 14 Apr 2014 New trial record